ASPG and acute lymphoblastic leukemia: These approaches have had success in AML (cladribine with LDAC + VEN alternating with AZA + VEN) [102] and acute lymphoblastic leukemia (hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone [HyperCVAD] alternating with methotrexate and cytarabine, with or without incorporation of tyrosine kinase inhibitors, VEN, nelarabine and/or asparaginase) [103–105], amongst others.